contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


notice-of-nexstim-plcs-h2-2025-half-year-and-2025-full-year-results

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Nothing has been moved up here. It was already announced last year that the H2 results would be released this Thursday. The annual report will then be out next Thursday. Nordnet, for example, shows somewhat random dates, but according to Nexstim’s own communications, there have been no changes.

On Thursday, everyone who can should tune in: Notice of Nexstim Plc’s H2 2025 Half-Year and 2025 Full Year Results Press release, Helsinki, 23 February 2026 at 12 PM (EET) Nexstim Plc (“Nexstim” or “Company”) will announce its half-year financial results for the six months ended 31 December 2025 as well as full-year financial results for the year ended 31 December 2025 on Thursday 26 February 2026 at 9:00 am Finnish time (EET). The company will hold two live webinars for media, investors, and analysts on Thursday 26 February 2026. CEO Mikko Karvinen and CFO Joonas Juokslahti will present the financial and operational results followed by a Q&A session. The first live webinar will be in Finnish, and it takes place at 10:30 am EET. The second live webinar will be in English at 3 pm EET. Webinar details: To attend the webinars, please register via the links below. Webinar in Finnish on Thursday 26 February 2026 at 10:30 am (EET): Sign up here >> Webinar in English on Thursday 26 February 2026 at 3:00 pm (EET): Sign up here >>

This new certification will presumably also increase the amount of guaranteed sales margin. Naturally, it has no impact on the share price, as is the case with any other particularly good news regarding Nexstim.

Here are Antti’s comments on Nexstim receiving MDR certification in the EU for its NBS 6 system for post-operative rehabilitation. Nexstim announced on Thursday that it has received MDR certification in the EU for its NBS 6 system for post-operative rehabilitation. The certification enables the marketing and sale of the equipment in the EU for upper limb motor rehabilitation following brain tumor surgery. Customers can now use the system for both pre-operative mapping and patient rehabilitation when surgery has caused issues with upper limb functionality. The news supports our growth forecasts and, in our assessment, increases the attractiveness of the equipment through the diversification of indications.                   Inderes              Nexstimin NBS 6 sai MDR-sertifioinnin leikkauksen jälkeiseen kuntoutukseen -...    NBS 6 -laitteiston käyttö laajenee aivoleikkauksen jälkeiseen kuntoutukseen.

Heidelberg University Hospital professor on LinkedIn:                    linkedin.com              #braintumor #glioma #glioblastoma #brainmetastases #arteriovenousmalformation...    Our original and world’s first study results on brain tumor patients with motor weakness just received CE marking and MDR approval.  Reducing transcallosal inhibition to aid motor recovery for neurosurgical patients   About 10 years ago, our group on...

A quick look at some figures (so there may be errors): In Europe, an estimated 82,000 – 85,000 new brain tumors or central nervous system tumors are diagnosed annually. It is difficult to provide an exact, continent-wide figure for the number of resected (operated) tumors, as not all tumors are suitable for surgery, but surgery is the primary and most important form of treatment for most solid tumors. Malignant brain cancers alone account for approximately 23,000 – 27,700 diagnosed cases per year in Europe. According to statistics, approximately 4.3% of patients develop new motor deficits following surgery that require rehabilitation. From Nexstim’s press release: Also, researchers report a stronger treatment effect for patients with proven ischemia on the postoperative MRI. And regarding ischemia itself: Post-brain tumor surgery ischemia (i.e., oxygen deficiency and tissue damage caused by a disturbance in cerebral blood circulation) is a common phenomenon that is observed on MRIs significantly more often than it causes visible symptoms. The frequency of detection depends on how it is defined:   Ischemia detectable in imaging: New ischemic changes are detected in up to 31–48% of patients in postoperative magnetic resonance imaging (DWI images).   In re-operations (recurrent tumors), the figure is significantly higher, up to 80%.   In low-grade gliomas (LGG), ischemia is found in approximately 23%.     Symptomatic ischemia (cerebral infarction): Clinically significant cerebral infarctions causing clear neurological symptoms occur less frequently, in an estimated 5.4–18.2% of patients.   Effect of location: Ischemia is most common in surgeries where the tumor is located near major blood vessels, such as the insula or the temporal lobe. In these areas, the risk of ischemia can be 23–57%.   Since we are on an investment forum, someone wiser than myself can calculate what kind of potential additional usage/sales this could bring,

This is indeed very good news. There is already a significant number of NBS 5 hardware systems globally, and this provides a strong impetus for upgrading them to the 6th generation. For the 6-series units already sold, software is being sold in turn = high-margin business. Great stuff!

Nexstim

Press release, Helsinki, 23 February 2026 at 12 PM (EET)Notice of Nexstim Plc’s H2 2025 Half-Year and 2025 Full Year ResultsNexstim Plc ("Nexstim" or "Company") will announce its half-year financial...

Press release, Helsinki, 23 February 2026 at 12 PM (EET)Notice of Nexstim Plc’s H2 2025 Half-Year and 2025 Full Year ResultsNexstim Plc ("Nexstim" or "Company") will announce its half-year financial results for the six months ended 31 December 2025 as well as full-year financial results for the year ended 31 December 2025 on Thursday 26 February 2026 at 9:00 am Finnish time (EET).The company will hold two live webinars for media, investors, and analysts on Thursday 26 February 2026. CEO Mikko Karvinen and CFO Joonas Juokslahti will present the financial and operational results followed by a Q&amp;A session.The first live webinar will be in Finnish, and it takes place at 10:30 am EET. The second live webinar will be in English at 3 pm EET.Webinar details:To attend the webinars, please register via the links below.Webinar in Finnish on Thursday 26 February 2026 at 10:30 am (EET): <a href="https://nexstim.wistia.com/live/events/vow6tu5jss">Sign up here &gt;&gt;</a>Webinar in English on Thursday 26 February 2026 at 3:00 pm (EET): <a href="https://nexstim.wistia.com/live/events/3oe30t43oq">Sign up here &gt;&gt;</a>Further information is available on the website <a>www.nexstim.com</a>, or by contacting:Mikko Karvinen, CEO+358 50 326 4101<a href="mailto:mikko.karvinen@nexstim.com">mikko.karvinen@nexstim.com</a>About Nexstim PlcNexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.Nexstim shares are listed on Nasdaq First North Growth Market Finland.For more information, please visit&nbsp;<a href="http://www.nexstim.com/">www.nexstim.com</a> <div> <hr> <div>Attachments</div> <div><a href="https://storage.googleapis.com/inderes-widgets-prod-assets/nexstim/attachments/cf4dd56b-799b-4070-b05a-0920e661d46d/nexstim-plc-press-release-notice-of-h2-fy-2025-results-23022026-final.pdf">Nexstim Plc_Press release_Notice of H2 FY 2025 results_23022026_FINAL.pdf</a></div> </div>